NASDAQ$RARE
Ultragenyx Pharmaceutical Inc. · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Ultragenyx reported strong revenue growth in Q4 2024, driven by key product sales, but continued to post a net loss.
Ultragenyx delivered $164,877,000 in revenue for Q4 2024, a 29% YoY increase, primarily fueled by Crysvita and Dojolvi sales. Despite higher revenue, the company reported a net loss of $133,385,000, with increased R&D and operating expenses.
- Total revenue grew 29% YoY to $164,877,000.
- Crysvita and Dojolvi saw strong revenue growth of 23% and 34% YoY, respectively.
- Net loss narrowed to $133,385,000, despite increased operating expenses.
- 2025 guidance projects revenue growth of 14-20% YoY.
Headline financials
Revenue & EPS history
Ultragenyx · Revenue · Quarterly
$165M
Revenue by segment
Ultragenyx · $98.1M total across 4 segments · Q3 2023
- Crysvita Revenue$74.9M+16.1%76.4%
- Dojolvi Revenue$16.6M+24.7%16.9%
- Mepsevii Revenue$5.63M-6.8%5.7%
- Evkeeza Revenue$963K—1.0%
Forward guidance
Ultragenyx expects 2025 revenue growth of 14-20%, with focused investments in commercial launches and late-stage clinical programs.
Tailwinds
- Total revenue projected to reach $640M-$670M.
- Crysvita revenue expected to grow to $460M-$480M.
- Dojolvi revenue guidance set at $90M-$100M.
- Expense management prioritized to reduce net cash burn.
- Multiple late-stage clinical trials progressing as planned.
Headwinds
- Net losses likely to continue despite revenue growth.
- Higher R&D and SG&A expenses expected to persist.
- Regulatory uncertainties around gene therapy approvals.
- Dependence on partner collaborations for key products.
- Potential market challenges in expanding product adoption.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-1.2%
Avg return
Earnings day
-0.5%
Avg return
5 days after
+0.1%
Avg return
30 days after
42%
20 / 48 earnings
Positive
+14.7%
Q1 2015
Best reaction
-18.9%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | +5.2% | -12.5% | |
| Q4 2025 | -12.7% | -13.0% | -9.2% | |
| Q3 2025 | -1.5% | -1.6% | +12.1% | |
| Q1 2025 | -4.8% | +2.9% | +6.0% | |
| Q4 2024 | -2.4% | +1.8% | -9.6% | |
| Q3 2024 | -1.1% | -1.4% | -7.3% | |
| Q2 2024 | +12.1% | +10.6% | +26.1% | |
| Q1 2024 | -1.3% | -3.1% | -7.3% | |
| Q4 2023 | +7.1% | +4.8% | +3.7% | |
| Q3 2023 | +7.7% | +5.7% | +11.4% | |
| Q2 2023 | -11.1% | -16.9% | -10.8% | |
| Q1 2023 | +9.0% | +8.6% | +17.4% | |
| Q4 2022 | +10.2% | +2.9% | -12.8% | |
| Q3 2022 | -9.0% | -16.4% | -4.2% | |
| Q2 2022 | +4.9% | +0.9% | -2.6% | |
| Q1 2022 | -18.9% | -24.5% | -27.5% | |
| Q4 2021 | -2.5% | -1.6% | -12.5% | |
| Q3 2021 | +0.0% | -3.1% | -8.0% | |
| Q2 2021 | +4.9% | +10.9% | +24.8% | |
| Q1 2021 | -0.5% | +7.5% | -11.4% | |
| Q4 2020 | -10.1% | -13.7% | -24.1% | |
| Q3 2020 | +4.1% | +10.1% | +31.3% | |
| Q2 2020 | +2.5% | +10.4% | +12.4% | |
| Q1 2020 | -2.4% | +4.1% | +8.1% | |
| Q4 2019 | -2.8% | -2.8% | -31.1% | |
| Q3 2019 | -7.9% | -4.6% | +5.0% | |
| Q2 2019 | -7.6% | -3.6% | -9.6% | |
| Q1 2019 | -8.0% | -5.7% | -15.4% | |
| Q4 2018 | +6.8% | +5.6% | +21.9% | |
| Q3 2018 | +0.9% | -3.0% | -6.4% | |
| Q2 2018 | -9.5% | -2.5% | +6.8% | |
| Q1 2018 | +6.1% | +17.7% | +42.3% | |
| Q4 2017 | -1.7% | +1.6% | +9.0% | |
| Q3 2017 | +3.2% | -5.2% | +7.7% | |
| Q2 2017 | -5.4% | -10.6% | -27.4% | |
| Q1 2017 | +2.0% | +2.5% | -5.1% | |
| Q4 2016 | +0.2% | +0.2% | +10.2% | |
| Q2 2016 | -2.2% | +0.2% | +2.5% | |
| Q1 2016 | +0.6% | — | — | |
| Q4 2015 | -0.7% | — | — | |
| Q3 2015 | -6.1% | — | — | |
| Q2 2015 | -3.8% | — | — | |
| Q1 2015 | +14.7% | — | — | |
| Q4 2014 | -7.2% | — | — | |
| Q3 2014 | -4.2% | — | — | |
| Q2 2014 | +1.9% | — | — | |
| Q1 2014 | -8.5% | — | — | |
| Q4 2013 | -8.4% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro